vs
BALCHEM CORP（BCPC）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BALCHEM CORP的季度营收约是BRC Group Holdings, Inc.的1.4倍（$263.6M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 14.9%，领先33.1%），BALCHEM CORP同比增速更快（9.8% vs -21.9%），过去两年BALCHEM CORP的营收复合增速更高（4.9% vs -15.4%）
Balchem Corp是一家全球特种化学品与营养原料供应商，核心业务覆盖人类营养、动物保健、制药、工业应用四大领域，为北美、欧洲、亚太等地区的客户提供定制化专用原料产品。
BCPC vs RILY — 直观对比
营收规模更大
BCPC
是对方的1.4倍
$188.3M
营收增速更快
BCPC
高出31.7%
-21.9%
净利率更高
RILY
高出33.1%
14.9%
两年增速更快
BCPC
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $263.6M | $188.3M |
| 净利润 | $39.2M | $90.3M |
| 毛利率 | 35.6% | 79.5% |
| 营业利润率 | 19.8% | 32.3% |
| 净利率 | 14.9% | 47.9% |
| 营收同比 | 9.8% | -21.9% |
| 净利润同比 | 16.8% | 1710.8% |
| 每股收益（稀释后） | $1.21 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCPCRILY
| Q4 25 | $263.6M | $188.3M | ||
| Q3 25 | $267.6M | $215.3M | ||
| Q2 25 | $255.5M | $188.2M | ||
| Q1 25 | $250.5M | $197.2M | ||
| Q4 24 | $240.0M | $241.0M | ||
| Q3 24 | $239.9M | $225.5M | ||
| Q2 24 | $234.1M | $256.0M | ||
| Q1 24 | $239.7M | $263.4M |
净利润BCPCRILY
| Q4 25 | $39.2M | $90.3M | ||
| Q3 25 | $40.3M | $91.1M | ||
| Q2 25 | $38.3M | $139.5M | ||
| Q1 25 | $37.1M | $-10.0M | ||
| Q4 24 | $33.6M | $-5.6M | ||
| Q3 24 | $33.8M | $-284.4M | ||
| Q2 24 | $32.1M | $-433.6M | ||
| Q1 24 | $29.0M | $-49.2M |
毛利率BCPCRILY
| Q4 25 | 35.6% | 79.5% | ||
| Q3 25 | 35.7% | 83.7% | ||
| Q2 25 | 36.4% | 81.3% | ||
| Q1 25 | 35.2% | 81.4% | ||
| Q4 24 | 36.0% | 79.8% | ||
| Q3 24 | 35.6% | 82.1% | ||
| Q2 24 | 35.5% | 84.5% | ||
| Q1 24 | 34.0% | 85.3% |
营业利润率BCPCRILY
| Q4 25 | 19.8% | 32.3% | ||
| Q3 25 | 20.4% | 30.4% | ||
| Q2 25 | 20.1% | 5.7% | ||
| Q1 25 | 20.4% | -31.2% | ||
| Q4 24 | 19.8% | -69.2% | ||
| Q3 24 | 20.0% | -36.4% | ||
| Q2 24 | 19.6% | -90.8% | ||
| Q1 24 | 17.4% | -6.1% |
净利率BCPCRILY
| Q4 25 | 14.9% | 47.9% | ||
| Q3 25 | 15.1% | 42.3% | ||
| Q2 25 | 15.0% | 74.1% | ||
| Q1 25 | 14.8% | -5.1% | ||
| Q4 24 | 14.0% | -2.3% | ||
| Q3 24 | 14.1% | -126.1% | ||
| Q2 24 | 13.7% | -169.4% | ||
| Q1 24 | 12.1% | -18.7% |
每股收益（稀释后）BCPCRILY
| Q4 25 | $1.21 | $2.78 | ||
| Q3 25 | $1.24 | $2.91 | ||
| Q2 25 | $1.17 | $4.50 | ||
| Q1 25 | $1.13 | $-0.39 | ||
| Q4 24 | $1.03 | $-0.01 | ||
| Q3 24 | $1.03 | $-9.39 | ||
| Q2 24 | $0.98 | $-14.35 | ||
| Q1 24 | $0.89 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $1.3B | $-171.5M |
| 总资产 | $1.7B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCPCRILY
| Q4 25 | $74.6M | $226.6M | ||
| Q3 25 | $65.1M | $184.2M | ||
| Q2 25 | $65.4M | $267.4M | ||
| Q1 25 | $49.9M | $138.3M | ||
| Q4 24 | $49.5M | $146.9M | ||
| Q3 24 | $73.7M | $159.2M | ||
| Q2 24 | $63.7M | $236.9M | ||
| Q1 24 | $60.3M | $190.7M |
总债务BCPCRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BCPCRILY
| Q4 25 | $1.3B | $-171.5M | ||
| Q3 25 | $1.3B | $-260.5M | ||
| Q2 25 | $1.3B | $-351.7M | ||
| Q1 25 | $1.2B | $-496.8M | ||
| Q4 24 | $1.1B | $-488.2M | ||
| Q3 24 | $1.2B | $-497.6M | ||
| Q2 24 | $1.1B | $-218.3M | ||
| Q1 24 | $1.1B | $228.4M |
总资产BCPCRILY
| Q4 25 | $1.7B | $1.7B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.6B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B | ||
| Q1 24 | $1.6B | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.3M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.72× | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BCPCRILY
| Q4 25 | $67.3M | $26.2M | ||
| Q3 25 | $65.6M | $-60.6M | ||
| Q2 25 | $47.3M | $-25.6M | ||
| Q1 25 | $36.5M | $184.0K | ||
| Q4 24 | $52.3M | $-2.7M | ||
| Q3 24 | $51.3M | $19.5M | ||
| Q2 24 | $45.0M | $111.5M | ||
| Q1 24 | $33.4M | $135.4M |
现金转化率BCPCRILY
| Q4 25 | 1.72× | 0.29× | ||
| Q3 25 | 1.63× | -0.66× | ||
| Q2 25 | 1.23× | -0.18× | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
